Dataset Information


Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.

ABSTRACT: Randomized trial data demonstrate the gain of extended duration anticoagulation in patients with venous thromboembolic events (VTE); however, real-world data are limited.Assess the risk of recurrent VTE and major bleeding in a real-world setting of patients who experienced unprovoked VTE and received extended treatment with rivaroxaban.US claims databases (February 2011-April 2015) were used in this retrospective study. The study population included adult patients initiated on rivaroxaban within 7 days after their first unprovoked VTE (ie, deep vein thrombosis, pulmonary embolism) and received ?3 months continuous rivaroxaban treatment (index date: end of 3-month treatment). Patients who were treated beyond 3 months formed the continued cohort and the remainder formed the discontinued cohort (ie, discontinued at 3 months). Adjusted Kaplan-Meier rates for recurrent VTE and major bleeding events were compared between cohorts with confounders being controlled through a propensity score weighting approach.Patients in the continued cohort (N = 3763) had significantly lower rates of recurrent VTE than those who discontinued (N = 1051): 0.57% vs 1.19% (P = .042), 1.07% vs 2.10% (P = .017), and 1.45% vs 2.60% (P = .023) at 3, 6, and 12 months, respectively. No significant differences in the rate of major bleeding were observed between cohorts. A sensitivity analysis among unprovoked VTE patients receiving rivaroxaban for ?6 months showed similar results.Continued rivaroxaban treatment beyond an initial 3- or 6-month treatment period significantly lowered the risk of recurrent VTE without a significant increase of major bleeding, compared to treatment discontinued at 3 or 6 months.


PROVIDER: S-EPMC6055557 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC6283241 | BioStudies
2019-01-01 | S-EPMC6524913 | BioStudies
2018-01-01 | S-EPMC6020936 | BioStudies
2019-01-01 | S-EPMC6718768 | BioStudies
| S-EPMC5318467 | BioStudies
1000-01-01 | S-EPMC5947542 | BioStudies
2018-01-01 | S-EPMC6046599 | BioStudies
2015-01-01 | S-EPMC4654552 | BioStudies
2019-01-01 | S-EPMC6611364 | BioStudies
| S-EPMC7409038 | BioStudies